Corpus Intelligence IC Memo — SOUTHEASTHEALTH 2026-04-26 04:03 UTC
IC Memo — SOUTHEASTHEALTH
Investment Committee Memorandum | MO | 232 beds | Grade C | EBITDA uplift $24.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SOUTHEASTHEALTH

CCN 260110 | CAPE GIRARDEAU, MO | 232 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SOUTHEASTHEALTH is a 232-bed under-performing / distressed in CAPE GIRARDEAU, MO with $335.2M in net patient revenue and a -15.2% operating margin. The hospital serves a payer mix of 37.4% Medicare, 7.5% Medicaid, and 55.1% commercial.

Thesis: Undervalued. Our ML models identify $24.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -15.2% to -7.8% (+736bps).

Net Revenue HCRIS$335.2M
Current EBITDA COMPUTED$-50.8M
Operating Margin COMPUTED-15.2%
Occupancy HCRIS39.1%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS28.7%
Distress Probability ML51.9%

2. Market Context & Competitive Position

138
MO Hospitals
-6.2%
State Median Margin
34
Comparable Hospitals

MO has 138 Medicare-certified hospitals with a median operating margin of -6.2%. The target's margin of -15.2% places it below the state median. Among 34 size-comparable peers (116-464 beds), the median margin is -2.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (116-464), prioritizing same-state peers. 34 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SOUTHEASTHEALTH (Target)MO232$335.2M-15.2%
CHILDRENS MERCY HOSPITALMO328$1.44B30.5%
ST. LOUIS CHILDRENS HOSPITALMO445$886.1M6.4%
SSM SAINT LOUIS UNIVERSITY HOSMO317$772.2M-6.4%
MISSOURI BAPTIST MEDICAL CENTEMO402$716.0M2.5%
HEARTLAND REGIONAL MEDICAL CENMO352$676.9M-6.2%
NORTH KANSAS CITY HOSPITALMO383$601.5M7.7%
FREEMAN OAK HILL HEALTH SYSTEMMO363$587.5M3.0%
ST. LUKES HOSPITALMO390$573.7M2.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $24.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$7.0M+210bp18mo
Cost to Collect4.5%2.5%$6.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$6.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$4.1M+122bp9mo
Clean Claim Rate88.0%96.0%$215K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$7.0M
Cost to Collect
$6.7M
Denial Rate Reduction
$6.6M
A/R Days Reduction
$4.1M
Clean Claim Rate
$215K
Total EBITDA Uplift$24.7M
Current EBITDA$-50.8M
+ RCM Uplift+$24.7M
Pro Forma EBITDA$-26.2M
Current Margin-15.2%
Pro Forma Margin-7.8%
WC Released (1x)$12.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-78.2M$-88.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-78.2M$-122.8M0.00x-100.0%
Bull Case9.0x11.0x$-70.4M$-66.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-70.4M$-93.7M0.00x-100.0%
Bear Case11.0x10.0x$-86.0M$-186.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-86.0M$-233.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 51.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 34 hospitals with 116-464 beds
  • Same-state prioritization (n=35)
  • Comp margins: P25=-12.4% / P50=-2.2% / P75=6.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.